A Phase I/II Study to Evaluate the Safety and Tolerability of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Number of participants with a change in Electrocardiography (ECG)
研究概览
简要总结
This is a Phase I/II, open label, single center study to assess the safety and tolerability of EXG34217 in bone marrow failure patients with telomere biology disorders.
详细描述
This is a Phase I/II, open label study in up to 12 subjects with telomere biology disorders with bone marrow failure. The study is open to all participants regardless of gender or ethnicity. Subjects who are enrolled but not evaluable will be replaced.
Subjects will sign a consent form prior to any study related procedure and will complete baseline screening assessments. Subjects for this study will not require any preparative regimen such as chemotherapy or radiation.
The study will be conducted in three parts
- Peripheral blood mononuclear cells (PBMNCs) collection; mobilization and apheresis,
- Ex vivo cell processing
- Processed cell infusion and post-infusion safety monitoring,
- Follow-up (Week 2, 3,4,5, Months 1, 2,3,4,5,6,9 and 12)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 12 years and above
- •Mild or moderate bone marrow failure defined by satisfying specific conditions.
- •Diagnosis of telomere biology disorders
排除标准
- •Women of child bearing potential or breastfeeding.
- •Patients with cancer who are on active chemotherapeutic treatment.
- •Patients with severe bone marrow failure.
- •Clonal cytogenetic abnormalities associated with MDS or AML on bone marrow examination.
- •Uncontrolled bacterial, viral or fungal infections.
- •Prior allogeneic marrow or stem cell transplantation.
- •Patients who are not eligible for G-CSF and plerixafor dosing.
- •Patients who are not eligible for the apheresis.
- •Patients currently taking or have taken danazol and androgens within 60 days prior to Day
- •Patients with any other clinically relevant acute or chronic diseases which could interfere with the patients' safety during the trial, expose them to undue risk, or which could interfere with study objectives.
- •Patients who have participated in another clinical trial with an investigational drug within the previous 30 days.
研究组 & 干预措施
EXG34217
single autologous CD34+ cells contacted ex vivo with EXG-001
干预措施: EXG34217 (Biological)
结局指标
主要结局
Number of participants with a change in Electrocardiography (ECG)
时间窗: Multiple times for the duration of the study (baseline through Month 12)
ECG (standard digital 12-lead in singlicate)
Number of participants with a change in in physical examination
时间窗: Multiple times for the duration of the study (baseline through Month 12)
Physical examination changes General appearance ,Head, eyes, ears, nose, and throat, Respiratory, Cardiovascular, Musculoskeletal, Abdomen, Neurologic, Extremities, Dermatologic, Lymphatic)
Number of participants with a change in clinical laboratory evaluations
时间窗: Multiple times for the duration of the study (baseline through Month 12)
Changes in clinical laboratory evaluations (Hematology, Blood chemistry, Coagulation, and Urinalysis)
Number of participants with adverse events -Safety by Incidence of Treatment-Emergent Adverse Events
时间窗: Multiple times for the duration of the study (baseline through Month 12)
Number of participants with treatment-related adverse events as assessed by CTCAE v4.03. Incidence and nature of adverse events, vital signs, weight.
Number of participants with a change of Immunogenicity
时间窗: Multiple times for the duration of the study (baseline through Month 12)
Change in Antibody against virus vector and transgene
次要结局
- Number of participants with a change in telomere length(Screening, Month1,3,6 and 12)
- Number of participants with improvement of blood counts.(Multiple times for the duration of the study (baseline through Month 12))